Biotech Values

[mouton29]

The upgrade has only a $62 price target, $10 from current price. What’s that, $40 or $50 million increase in market cap? Pfizer predicts $22 billion in Paxlovid revenue, if ENTA’s drug is superior and produces 10 percent of that in revenue (wildly conservative), a 20 percent probability would justify more than $10 upside.